Compare Expensify Inc (EXFY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Gilead Sciences, Inc. — how do they compare? Expensify Inc trades at $1.78 (market cap $170.21M), while Gilead Sciences, Inc. trades at $132.7 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 960.6× Expensify Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | GILD | |
|---|---|---|
Market Cap | $170.21M | $163.51B |
Sector | Technology | Health |
52-Week High | $2.33 | $155.80 |
52-Week Low | $0.75 | $108.22 |
Enterprise Value | $109.24M | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.755, down 3.04% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative profitability metrics with a -14.68% net income margin. Recent developments include AI-powered expense management expansions and a $25 million stock repurchase program, indicating strategic initiatives to drive growth.
The outlook remains cautious due to persistent unprofitability despite revenue stabilization around $140 million. Investment opportunities lie in operational efficiency gains and new product integrations, but risks include competitive pressure and the challenge of achieving sustainable profitability. Analyst sentiment is divided with equal buy/hold ratings, reflecting uncertainty about the company's turnaround potential.
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
